Videos

Alexis spoke in this segment of his Fall Clinical interview on takeaways from his presentation titled ‘Melasma and Other Hyperpigmentation Disorders.’

In this Fall Clinical interview, Alexis highlights several tips for clinicians covered in his session at the conference titled ‘30 Tips in 30 Minutes.’

This interview with Prince Adotama, MD, at Fall Clinical highlights several takeaways from his session on treating bullous pemphigoid.

In this segment of her Fall Clinical interview, Shahriari highlights a session IL-13 inhibition and management of atopic dermatitis.

This interview at Fall Clinical highlights a session on clinical pearls related to diagnosing prurigo nodularis in patients with skin of color.

This interview highlights the takeaways from Nestor’s Fall Clinical session titled ‘What Did 2025 Bring to the Table in Dermatology?’

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Vaidya describes the prognostic approach to pulmonary hypertension in the revised Echocardiographic Assessment of the Right Heart Guidelines.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

This October 16 Skin of Color Savvy highlights the often overlooked topic of curly hair in dermatology.

Santreva-ATK, the first wire-free endovascular revascularization catheter for crossing chronic total occlusions, is expected to begin sale in October 2025.

In this episode, sisters and dermatologists Mona and Neda Shahriari discuss mentorship, motherhood, and the meaning of sisterhood in medicine.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Little discusses 2 recently emerged therapies for TR, spotlighting the benefits and limitations associated with each procedure.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

Nijhoff discusses the positive results of the first portion of the phase 1/2/3 trial and its implications for the underserved T1D patient population.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.